Fusafungine
Chemical compound
From Wikipedia, the free encyclopedia
Fusafungine (INN), also known as fusafungin, is an active agent used in antibiotics for treatment of nasal and throat infection. It also possesses anti-inflammatory properties. Fusafungine is a mixture of enniatin cyclohexadepsipeptides made up of alternating D-α-hydroxyvaleric acid and L-N-methylamino acid residues,[1] produced by the ascomycete Fusarium lateritium, and marketed by Servier under the trade names Locabiotal, Bioparox, and Locabiosol.
| Clinical data | |
|---|---|
| Other names | Fusafungin |
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.014.306 |
| Chemical and physical data | |
| Formula | C33H57N3O9 |
| Molar mass | 639.831 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 125 to 129 °C (257 to 264 °F) |
| |
| |
| | |
According to a pooled analysis study done in the UK for the efficacy of fusafungine in rhinopharyngitis, it was found that the proportion of patients who showed an improvement in symptoms from Day 0 to Day 4 of infection was 61.5% with fusafungine vs. 46.8% when compared to a placebo.[2]
In February 2016, the European Medicines Agency recommended the withdrawal of fusafungine from the market due to rare but severe allergic reactions (mainly bronchospasms).[3]